DBV Technologies (NASDAQ:DBVT) Stock Gets Price Target Reduction from Guggenheim

DBV Technologies (NASDAQ:DBVT) had its price objective trimmed by Guggenheim from $51.00 to $46.00 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the company. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a report on Thursday. HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research note on Friday. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citizens Jmp cut their target price on shares of DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and an average target price of $45.25.

DBV Technologies Price Performance

DBVT opened at $9.49 on Friday. DBV Technologies has a 52 week low of $8.63 and a 52 week high of $26.18. The company has a market capitalization of $596.71 million, a PE ratio of -3.15 and a beta of -1.04. The firm has a 50-day simple moving average of $11.53 and a two-hundred day simple moving average of $16.93.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.56 million. DBV Technologies had a negative return on equity of 120.95% and a negative net margin of 5,392.17%. As a group, sell-side analysts expect that DBV Technologies will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada raised its position in shares of DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after acquiring an additional 2,928 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of DBV Technologies during the 3rd quarter valued at approximately $144,000. China Universal Asset Management Co. Ltd. increased its stake in DBV Technologies by 170.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company’s stock worth $249,000 after acquiring an additional 13,600 shares during the last quarter. Personal CFO Solutions LLC bought a new position in DBV Technologies during the 1st quarter valued at about $264,000. Finally, Cetera Investment Advisers increased its stake in DBV Technologies by 93.4% in the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after purchasing an additional 12,243 shares during the period. 71.74% of the stock is currently owned by institutional investors.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch in children ages 4–7 and requested Priority Review. The company also said it is accelerating commercial preparations, supporting the potential value of the product if approved. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
• Positive Sentiment: HC Wainwright raised its FY2028 earnings estimate to $1.25 per share from $1.15 and maintained a Buy rating, reflecting greater confidence in the company’s longer-term commercial outlook.
• Positive Sentiment: Guggenheim maintained a Buy rating and lowered its price target to $46 from $51. Despite the reduction, the target implies substantial upside from recent trading levels.
• Neutral Sentiment: DBV reported $165.7 million in cash and cash equivalents as of September 30, which management said should fund operations into the third quarter of 2027. However, the company remains dependent on future execution and regulatory progress.
• Negative Sentiment: Third-quarter EPS was a loss of $0.70, substantially worse than the consensus loss estimate of $0.26. Revenue of $1.60 million exceeded the $0.56 million estimate, but the company continues to report deeply negative profitability metrics. DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch
• Negative Sentiment: DBV disclosed heightened going-concern risk as liquidity constraints increase the possibility of dilutive financing. A new equity raise could pressure existing shareholders and likely contributes to the stock’s weakness. DBV Technologies Faces Heightened Going-Concern Risk
• Negative Sentiment: Citizens lowered its price target to $47 from $55 while maintaining a Market Outperform rating, citing third-quarter manufacturing risk. The target reduction reinforces concerns about execution ahead of a potential launch.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.